Obstructive Lung Disease

Is There an “Ideal” Cystic Fibrosis Candidate for Lung Transplantation?

By

Suzanne Bujara

Publish Date August 23, 2018

Lung transplantation can extend survival in patients with cystic fibrosis who have compromised lung function and increasing exacerbations.

Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes

By

Heidi Moore

Publish Date October 19, 2019

Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.

Lumacaftor-Ivacaftor Improves Lung Function in Cystic Fibrosis After 1 Year

Publish Date October 16, 2019

After one year of therapy, patients had improved lung function, increased BMI, and a reduced need for intravenous antibiotics.

New Clinical Tool Predicts 1- and 2-Year Mortality in Cystic Fibrosis

By

Virginia A. Schad, PharmD, RPh

Publish Date September 27, 2019

A novel clinical tool has been developed that uses patients’ overall health status and the risk for intermittent shock events to predict 1- and 2-year mortality in cystic fibrosis.

Comparing Efficacy of Once vs Thrice Daily Aminoglycosides in Cystic Fibrosis

By

Brandon May

Publish Date September 24, 2019

Once- and thrice-daily treatment with aminoglycosides appear to be equally effective for reducing pulmonary exacerbations in cystic fibrosis.

FDA to Review Elexacaftor, Tezacaftor, Ivacaftor Combination for Cystic Fibrosis

By

Steve Duffy

Publish Date August 26, 2019

The FDA has accepted for priority review the NDA for elexacaftor, tezacaftor and ivacaftor triple combination regimen for patients with cystic fibrosis.

Novel Triple Combination Therapy for Cystic Fibrosis Submitted for FDA Review

By

Steve Duffy

Publish Date July 25, 2019

The NDA for the investigational therapy elexacaftor (VX-445), for use in combination with tezacaftor and ivacaftor in the treatment of cystic fibrosis, has been submitted to the FDA.

Key Cystic Fibrosis Pathogens Reduced With Ivacaftor

Publish Date July 24, 2019

Ivacaftor use was linked to reductions in P. aeruginosa rates, prevalence of S. aureus, Aspergillus species.

Palivizumab Not Associated With Improved Long-Term Outcomes in Cystic Fibrosis

By

Sheila Jacobs

Publish Date July 18, 2019

Treatment with palivizumab was not associated with improved long-term outcomes in children with cystic fibrosis.